Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Dimopoulos, Meletios A., Roussou, Maria, Gavriatopoulou, Maria, Psimenou, Erasmia, Ziogas, Dimitrios, Eleutherakis-Papaiakovou, Evangelos, Fotiou, Despina, Migkou, Magdalini, Kanellias, Nikolaos, Panagiotidis, Ioannis, Ntalianis, Argyrios, Papadopoulou, Elektra, Stamatelopoulos, Kimon, Manios, Efstathios, Pamboukas, Constantinos, Kontogiannis, Sofoklis, Terpos, Evangelos, Kastritis, Efstathios
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5738981/
https://ncbi.nlm.nih.gov/pubmed/29296960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016003269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados